Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter De Cruz

Showing results (31-40 of 128) with videos related to

Pageof 13
Sort By:
Inflammatory Bowel Diseases|November 10, 2011
Serological antibodies in inflammatory bowel disease: a systematic reviewLani Prideaux, Peter De Cruz, Siew C Ng, et al.
Inflammatory Bowel Diseases|February 14, 2025
Upadacitinib in Autoimmune Enteropathy-A Case ReportSimone Chin, Julie Lokan, Darren Wong, et al.
Internal Medicine Journal|August 20, 2023
Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitisAli Eqbal, Patrick Hilley, Matthew Choy, et al.
Inflammatory Bowel Diseases|May 17, 2021
Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative ColitisPatrick Hilley, Robert Gilmore, Ashish Srinivasan, et al.
Internal Medicine Journal|January 12, 2024
Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?Patrick Hilley, Darren Wong, Ronald Ma, et al.
Journal of Crohn'S & Colitis|June 23, 2021
Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative ColitisRobert Gilmore, Patrick Hilley, Ashish Srinivasan, et al.
Journal of Crohn'S & Colitis|March 2, 2016
EHealth Technologies in Inflammatory Bowel Disease: A Systematic ReviewBelinda D Jackson, Kathleen Gray, Simon R Knowles, et al.
Inflammatory Bowel Diseases|February 21, 2020
Letter Re: Safety of Combination Biologic and Antirejection Therapy Post-liver Transplantation in Patients With Inflammatory Bowel DiseaseMatthew Peverelle, Chris Mills, Adam Testro, et al.
Alimentary Pharmacology & Therapeutics|May 24, 2020
Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis?Christopher F D Li Wai Suen, Matthew C Choy, Peter De Cruz
Alimentary Pharmacology & Therapeutics|February 27, 2020
Letter: infliximab induction regimens in steroid-refractory acute severe colitis-a propensity score analysisChristopher F D Li Wai Suen, Matthew C Choy, Peter De Cruz
Pageof 13

Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
Inflammatory Bowel Diseases|November 10, 2011
Serological antibodies in inflammatory bowel disease: a systematic reviewLani Prideaux, Peter De Cruz, Siew C Ng, et al.
Inflammatory Bowel Diseases|February 14, 2025
Upadacitinib in Autoimmune Enteropathy-A Case ReportSimone Chin, Julie Lokan, Darren Wong, et al.
Internal Medicine Journal|August 20, 2023
Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitisAli Eqbal, Patrick Hilley, Matthew Choy, et al.
Inflammatory Bowel Diseases|May 17, 2021
Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative ColitisPatrick Hilley, Robert Gilmore, Ashish Srinivasan, et al.
Internal Medicine Journal|January 12, 2024
Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?Patrick Hilley, Darren Wong, Ronald Ma, et al.
Journal of Crohn'S & Colitis|June 23, 2021
Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative ColitisRobert Gilmore, Patrick Hilley, Ashish Srinivasan, et al.
Journal of Crohn'S & Colitis|March 2, 2016
EHealth Technologies in Inflammatory Bowel Disease: A Systematic ReviewBelinda D Jackson, Kathleen Gray, Simon R Knowles, et al.
Inflammatory Bowel Diseases|February 21, 2020
Letter Re: Safety of Combination Biologic and Antirejection Therapy Post-liver Transplantation in Patients With Inflammatory Bowel DiseaseMatthew Peverelle, Chris Mills, Adam Testro, et al.
Alimentary Pharmacology & Therapeutics|May 24, 2020
Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis?Christopher F D Li Wai Suen, Matthew C Choy, Peter De Cruz
Alimentary Pharmacology & Therapeutics|February 27, 2020
Letter: infliximab induction regimens in steroid-refractory acute severe colitis-a propensity score analysisChristopher F D Li Wai Suen, Matthew C Choy, Peter De Cruz
Pageof 13